Evidence map›Paper›PMID 30924141›Full record

ArticleInternational journal of cancer2020

The systemic immune-inflammation index is associated with an increased risk of incident cancer-A population-based cohort study.

Jesse Fest, Rikje Ruiter, Marlies Mulder, Bas Groot Koerkamp, M Arfan Ikram, Bruno H Stricker, Casper H J van Eijck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jesse FestDepartment of Surgery, Erasmus MC University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-8842-6801
Rikje RuiterDepartment of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Marlies MulderDepartment of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Bas Groot KoerkampDepartment of Surgery, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
M Arfan IkramDepartment of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Bruno H StrickerDepartment of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Casper H J van EijckDepartment of Surgery, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several studies found that the systemic immune-inflammation index (SII) is a prognostic factor for mortality in patients with solid tumors. It is unknown whether an increased SII in generally healthy individuals reflects a risk for developing cancer. Our objective was to investigate the association between the SII and incident cancers in a prospective cohort study. Data were obtained from the Rotterdam Study; a population-based study of individuals aged ≥45 years, between 2002 and 2013. The SII at baseline was calculated from absolute blood counts. The association between the SII and the risk of any solid incident cancer during follow-up was assessed using Cox proportional hazard models. Individuals with a prior cancer diagnosis were excluded. Data of 8,024 individuals were included in the analyses. The mean age at baseline was 65.6 years (SD 10.5 years) and the majority were women. During a maximum follow-up period of 10.7 years, 733 individuals were diagnosed with cancer. A higher SII at baseline was associated with a 30% higher risk of developing a solid cancer (HR of 1.30 [95% CI; 1.11-1.53]), after adjustment for age, sex, socioeconomic status, smoking, BMI and type 2 diabetes. The absolute cumulative 10-year cancer risk increased from 9.7% in the lowest quartile of SII to 14.7% in the highest quartile (p-value = 0.009). The risk of developing cancer was persistent over time and increased for individuals with the longest follow-up. In conclusion, a high SII is a strong and independent risk indicator for developing a solid cancer.

Indexed as

AgedFemaleFollow-Up StudiesHumansInflammationInflammation MediatorsMaleMiddle AgedNeoplasmsNetherlandsProspective StudiesRisk FactorsSeverity of Illness IndexTime FactorsInflammation Mediatorscancer riskcirculatory markeretiologyinflammatory markersystemic immune-inflammation index

Identifiers

PMID30924141
PMCPMC6916270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.